Immunocore Ltd

This is the first-ever study in people for a new drug called IMC-P115C, designed to treat advanced cancers that have a specific marker called PRAME. The main goal is to test the drug's safety and see if it causes any serious side effects when given alone or with standard treatmen…

This study is testing a new type of immune therapy drug called IMC-R117C for people with advanced colorectal, esophageal, gastric, or ovarian cancers. The drug is designed to help the body's own immune cells find and attack cancer cells. Researchers will test the drug alone and i…

This study is testing whether a new drug called tebentafusp, given alone or with pembrolizumab, works better than standard care options for people with advanced melanoma that has worsened despite previous treatments. The trial will enroll 540 participants with specific genetic ma…

This Phase 3 trial is testing whether adding a new drug called brenetafusp (IMC-F106C) to the standard immunotherapy nivolumab works better than current treatments for advanced melanoma. It will enroll about 680 people with previously untreated, advanced melanoma who have a speci…